Platinum-based chemotherapy has been shown to provide survival benefits in advanced non-small cell lung cancer (NSCLC). Maintenance/consolidation chemotherapy in NSCLC has gained renewed interest with improved tolerability of chemotherapy and the addition of biologic agents. Various studies have evaluated the role of prolonged duration of chemotherapy as well as maintenance/consolidation strategies with both chemotherapy and biologic agents. The available data at this time demonstrates that maintenance or consolidation therapy can improve progression free survival; however this does not result consistently in an improved overall survival. We review the literature with regard to duration of therapy and use of maintenance/consolidation therapy in advanced NSCLC.
Belani, C.P., Brodowicz, T., Ciuleanu, T., Kim, J.H., Krzakowski, M.Laack, Y. et al. (2009) Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III Study in NSCLC. In ASCO 2009 . Orlando, FL; J Clin Oncol27: 18s (suppl; abstr CRA 8000).
2.
Brodowicz, T., Krzakowski, M., Zwitter, M., Tzekova, V., Ramlau, R., Ghilezan, N. et al. (2006) Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer52: 155-163.
3.
Cappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczesna, A., Juhasz, E. et al. (2009) SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol27:15s (suppl; abstr 8001).
4.
Fidias, P.M., Dakhil, S.R., Lyss, A.P., Loesch, D., Waterhouse, D., Cunneen, J. et al. (2009) Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol27: 591-598.
5.
Gatzemeier, U., Pluzanska, A., Szczesna, A., Kaukel, E., Roubec, J., De Rosa, F. et al. (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol25: 1545-1552.
6.
Giaccone, G., Herbst, R., Manegold, C., Scagliotti, G., Rosell, R., Miller, V. et al. (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACTI. J Clin Oncol22: 777-784.
7.
Hainsworth, J.D., Sosman, J.A., Spigel, D.R., Edwards, D.L., Baughman, C. and Greco, A. ( 2005) Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol23: 7889-7896.
8.
Herbst, R., Giaccone, G., Schiller, J., Natale, R.B., Miller, V., Manegold, C. et al. (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol27: 785-793.
9.
Herbst, R.S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B.E., Sandler, A. et al. (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol23: 5892-5899.
10.
Hida, T., Okamoto, I., Kashii, T., Satouchi, M., Ichinose, Y., Katakami, N. et al. (2008) Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group trial (WJTOG). In: ASCO 2008. Chicago, IL: J Clin Oncol26: 2008 (May 20 suppl; abstr LBA8012).
11.
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W. et al. (2004) Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med350: 2335-2342.
12.
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T. et al. (2008) Cancer statistics, 2008. CA Cancer J Clin58: 71-96.
13.
Marino, P., Pampallona, S., Preatoni, A., Cantoni, A. and Invernizzi, F. ( 1994) Chemotherapy vs supportive care in advanced non-small-cell lung cancer: results of a meta-analysis of the literature. Chest106: 861-865.
14.
Miller, K.D., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E.A. et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med357: 2666-2676.
15.
Miller, V.A., O’Connor, P., Soh, C. and Kabbinavar, F. ( 2009) A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol2718s, (suppl; abstr LBA8002).
16.
Non-small Cell Lung Cancer Collaborative Group ( 1995). Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials . BMJ311: 899-909.
17.
Park, J.O., Kim, S., Ahn, J.S., Suh, C., Lee, J.S., Jang, J.S. et al. (2007) Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum based chemotherapy in non-small cell lung cancer. J Clin Oncol25: 5233-5239.
18.
Phister, D.G., Johnson, D.J., Azzoli, C.G., Sause, W., Smith, T.J., Baker Jr, S. et al. (2004) American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: Update 2003. J Clin Oncol22: 330-353.
19.
Pirker, R., Pereira, J.R., Szczesna, A., von Pawel, J., Krzakowski, M., Ramlau, R. et al. (2009) Cetuximab plus chemotherapy in patients with advanced non-small cell lung cancer (FLEX): an open-labeled randomized phase III trial. Lancet373: 1525-1531.
20.
Rapp, E., Pater, J.L., Willan, A., Cormier, Y., Murray, N., Evans, W.K. et al. (1988) Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol6: 633-641.
21.
Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V. et al. (2009) A phase III trial of cisplatin and gemcitabine with either placebo or bevacizumab as first line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol27: 1227-1234.
22.
Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A. et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med355: 2542-2550.
23.
Schiller, J.H., Harrington, D., Belani, C.P., Langer, C., Sandler, A., Krook, J. et al. (2002) Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med346: 92-98.
24.
Smith, I.A., O’Brien, M.E., Talbot, D.C., Nicolson, M.C., Mansi, J.L., Hickish, T.F. et al. (2001) Duration of chemotherapy in advanced non-small cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol19: 1336-1343.
25.
Socinski, M.A., Schell, M.J., Peterman, A., Bakri, K., Yates, S., Gitten, R. et al. (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small cell lung cancer. J Clin Oncol20: 1335-1343.
26.
Soon, Y.Y., Stockler, M.R., Askie, L.M. and Boyer, M.J.(2009) Duration of chemotherapy for advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized trials. J Clin Oncol27: 3277-3283.
27.
Von Plessen, C., Bergman, B., Andresen, O., Bremnes, R.M., Sundstrom, S., Gilleryd, M. et al. (2006) Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer95: 966-973.
28.
Westeel, V., Quoix, E., Moro-Sibilot, D., Mercier, M., Breton, J.L., Debieuvre, D. et al. (2005) Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst97: 499-506.
